( Editorial: --> 8642 )
ZAGREB, Sept 7 (Hina) - Croatia's pharmaceutical giant Pliva on
Monday signed a licensing agreement with Receptron, Inc., a
California-based biotechnological company.
The agreement gives Pliva exclusive rights to the development of
medicines which act similarly to endogenous trombopoetine (TPO),
but have additional advantages as well.
In line with the agreement, Pliva will assist Receptron in
research, pay out exclusive rights and royalties from future
sales.
TPO is a growth agent which stimulates the production of blood
vessels.
It should also replace transfusions which are expensive and high-
risk due to possibilities of HIV and hepatitis infections.
It is expected the TPO product's market potential will be in excess
of US$500 million.
(hina) ha jn/sp
071640 MET sep 98
ZSE: Uz solidan promet, Crobexi stagniraju
Europski festival novinarstva i medijske pismenosti u Zagrebu počinje 27. veljače
Eksplozija kod ruskog konzulata u Marseilleu, Rusija sumnja na terorizam
BiH: Uhićen nakon što je pucao na policiju, bacio bombu i ukrao policijsko vozilo
Hrvatski sabor ovaj tjedan o nekoliko izvješća i Programskom vijeću HRT-a
EU ustrajna u pomoći Ukrajini, najavljuje novu pomoć
ATP ljestvica: Sinner i dalje na vrhu, Ćorić 143.
WTA ljestvica: Vekić ostala 20., Sabalenka na vrhu, Andrejeva deveta
Izvjestitelj EP-a Tonino Picula počeo posjet Srbiji, bez susreta s Vučićem
SVJETSKA TRŽIŠTA: Europske burze blago porasle, u fokusu Njemačka